Enlivex Takes a Stand Against Misleading Information
Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a leading clinical-stage company specializing in macrophage reprogramming immunotherapy, has recently faced a significant challenge. Reports circulating falsely indicate that the company has suspended its stock trading due to internal inquiries. Such claims originated from a misleading news source, which has raised concerns among investors. Enlivex swiftly confirmed that these allegations are completely unfounded and that their trading activities on both the Tel Aviv Stock Exchange and NASDAQ remain uninterrupted.
The Company’s Response
Oren Hershkovitz, the CEO of Enlivex, expressed deep concern regarding the implications of these false assertions on public perception and investor confidence. "This is a blatant attempt to manipulate public perception and mislead investors," he stated firmly. Enlivex takes this issue seriously and is prepared to initiate legal actions against the entities responsible for disseminating this misinformation. Ensuring transparency and trust is of paramount importance to the company as they strive to protect their shareholders and maintain their operational integrity.
Staying True to Their Mission
Despite the distractions caused by these rumors, Enlivex remains committed to advancing its innovative therapies. The company is focused on its flagship product, Allocetra™, which has the potential to transform treatment options for patients suffering from conditions like osteoarthritis—a disease that currently leaves many with limited alternatives.
About Allocetra™
Allocetra™ is a pioneering, off-the-shelf cell therapy designed to reprogram macrophages to restore balance within the immune system. This reprogramming is vital, restoring non-homeostatic macrophages, a factor that plays a crucial role in resolving dire health conditions. With Allocetra™, Enlivex aims to provide effective treatment solutions that can benefit millions of patients who otherwise have few options.
Official Communications and Credibility
Enlivex emphasizes the importance of relying on official company communications. Investors are advised to consult credible sources such as press releases, filings with the U.S. Securities and Exchange Commission, and statements issued directly by the company. This recommendation is not just a precaution but a vital strategy for safeguarding investor interests from deceptive reports.
For Investor Support
In matters of concern or inquiries, Enlivex encourages stakeholders to reach out directly to Shachar Shlosberger, the CFO. Maintaining open lines of communication is essential for the company as it navigates this challenging period.
Enlivex: A Brief Overview
Enlivex is dedicated to the development of macrophage reprogramming immunotherapy. This innovative approach has been a beacon of hope for patients. In recent times, the company has increased its efforts to raise awareness about its groundbreaking work, which could reshape traditional treatment methodologies with its cutting-edge technology.
Contact Information
For any investor relations needs, reach out to:
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.
Email: shachar@enlivexpharm.com
For broader inquiries, you can also connect with:
Dave Gentry, CEO
RedChip Companies Inc.
Phone: 1-407-644-4256
Email: ENLV@redchip.com
Frequently Asked Questions
What is the current status of Enlivex operations?
Enlivex operations continue as normal, with no disruptions in stock trading.
What action is Enlivex taking against false news reports?
The company is pursuing legal actions against those responsible for publishing the misleading reports.
What is the primary focus of Enlivex Therapeutics?
Enlivex is focused on developing Allocetra™, aimed at reprogramming macrophages to help resolve immunological disorders.
Who can I contact for investor-related inquiries at Enlivex?
For inquiries, contact Shachar Shlosberger, the CFO, via email.
How can I learn more about Enlivex's products and technology?
For detailed information, please visit the Enlivex website at www.enlivex.com.
